Thomas West
About Thomas A. West
Independent director of SI-BONE; age 61; appointed June 2024; currently President and CEO of Nalu Medical (Aug 2022–present). Previously CEO/Director at Intersect ENT (2019–2022), Worldwide President, Diagnostic Solutions at Hologic (2015–2019), and a 23-year Johnson & Johnson veteran (including LifeScan Division President roles and WW Strategy & BD) . He is an independent director under Nasdaq standards; Board confirms no disqualifying relationships; he serves in Class III with a term continuing to the 2027 annual meeting; Board met four times in 2024 and all directors, including West, attended at least 75% of Board/committee meetings . Education: B.A. in Politics & Economics (Princeton) and MBA (Wharton) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Intersect ENT, Inc. | President, CEO and Director | 2019–2022 | Led company to sale to Medtronic (May 2022) |
| Hologic, Inc. | Worldwide President, Diagnostic Solutions | 2015–2019 | Ran global diagnostics division |
| Johnson & Johnson (LifeScan/Diabetes Solutions) | Division President (LifeScan North America; LifeScan EMEA); WW President, Strategy & BD (Diabetes Solutions) | 23-year tenure (roles across career) | Commercial P&L leadership and corporate development |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Nalu Medical, Inc. (private) | President, CEO, Director | Aug 2022–present | Neurostimulation for chronic pain |
| Inogen, Inc. (public) | Director | Prior service (dates not specified) | Former public-company directorship |
| Orthofix Medical, Inc. (public) | Director | Prior service (dates not specified) | Former public-company directorship |
| AdvaMed; Biocom California | Director (trade associations) | Prior service | Medical technology industry bodies |
Board Governance
- Independence/tenure: Board determined West is independent under Nasdaq; no material relationships identified; Class III director continuing to 2027 annual meeting .
- Committees: Member, Compensation Committee (2024); Compensation Committee is fully independent; chaired by Tim Davis; West co-signed the Compensation Committee report .
- Attendance/engagement: Board met four times in 2024; all directors met or exceeded 75% attendance on Board and committees; Compensation Committee meets at least four times annually and regularly in executive session .
- Leadership structure: Independent Lead Director (Timothy E. Davis); Chair is non-executive (Jeffrey Dunn) .
- Skills matrix: West brings medical device industry knowledge, M&A experience, regulatory/clinical exposure, and global business experience per the Board skills matrix .
- Shareholder support: Elected at the 2024 annual meeting with 35,195,079 “For” vs 142,225 “Withheld” votes .
Fixed Compensation (Director)
Policy and 2024 amounts:
| Item | Amount | Notes |
|---|---|---|
| Board annual cash retainer | $45,000 | Paid quarterly; pro-rated for partial year service |
| Committee fees – Compensation (Member) | $7,000 | Annual member fee; chair fee $15,000 |
| Lead Independent Director premium | $5,000 | Not applicable to West |
| Chair of the Board premium | $45,000 | Not applicable to West |
| West – 2024 cash fees earned | $26,000 | Reflects pro-rated service from June 26, 2024 |
Performance Compensation (Director)
Equity is time-based (no performance metrics for directors). Initial onboarding grant and ongoing annual grants:
| Element | Grant details | Vesting | Value/Units |
|---|---|---|---|
| Initial RSU grant (policy) | Granted to new non-employee directors upon joining | Vests ratably over 36 months | Target value $250,000 |
| Annual RSU grant (policy) | Granted at each annual meeting to continuing directors | Vests ~one year from grant | Target value $120,000 |
| West – initial director RSU (actual) | Granted June 26, 2024 (effective election date) | Per policy (36 months, subject to service) | 18,315 RSUs; grant-date FV $228,571; $12.48 per RSU |
Performance metrics linked to director compensation: None (time-based RSUs only) .
Other Directorships & Interlocks
| Company/Body | Current/Past | Role | Interlock/Notes |
|---|---|---|---|
| Inogen, Inc. | Past | Director | Former public board; no disclosed interlocks with SIBN executives |
| Orthofix Medical, Inc. | Past | Director | Former public board; no disclosed interlocks with SIBN executives |
| AdvaMed; Biocom California | Past | Director | Trade associations |
| Compensation Committee interlocks (SIBN) | N/A | Committee member in 2024 | Company discloses no interlocks; none of the members were officers/employees |
Expertise & Qualifications
- Medtech operating leadership (devices, diagnostics), M&A and corporate development, regulatory/clinical oversight, global commercial experience; per Board skills matrix, West’s competencies include Medical Device Industry Knowledge, Mergers & Acquisitions, Regulatory/Clinical, and Global Business Experience .
- Education: B.A. (Princeton) and MBA (Wharton) .
Equity Ownership
| Measure | Amount/Status | As-of | Notes |
|---|---|---|---|
| Beneficial ownership – Shares owned | 3,053 shares (<1%) | March 31, 2025 | Less than 1% of outstanding |
| Right to acquire within 60 days | None | March 31, 2025 | No options/RSUs exercisable within 60 days |
| Outstanding RSUs (unvested) | 16,789 RSUs | Dec 31, 2024 | Director RSUs outstanding at year-end |
| Hedging/pledging | Prohibited by policy | Policy | Applies to directors, officers, employees |
| Ownership guidelines | 3x annual Board cash retainer; 5 years to comply | Policy | As of FY2024, all non-employee directors satisfied or on track |
Governance Assessment
- Strengths: Independent status; active role on an independent Compensation Committee with robust processes and independent consultant (Compensia); strong shareholder support at election; attendance threshold met; rigorous policies on hedging/pledging and stock ownership guidelines support alignment .
- Compensation governance signals: Company engaged shareholders (2024) and adjusted metrics (greater Adjusted EBITDA weight and 2025 financial-metric PSUs); say‑on‑pay support was 98.3% in 2024, indicating investor confidence in compensation oversight during West’s committee tenure in 2024 .
- Conflicts/related parties: Audit Committee reports no related‑party transactions >$120,000 since start of FY2024; Board reaffirmed independence after reviewing relationships; hedging/pledging is prohibited, and no pledging is disclosed for directors, including West .
RED FLAGS: None identified in filings—no attendance shortfalls, related‑party transactions, or hedging/pledging exceptions disclosed for West .